NDAINTRAVENOUSEMULSION
Approved
Nov 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Neurokinin 1 Antagonists
Pharmacologic Class:
Substance P/Neurokinin-1 Receptor Antagonist
Clinical Trials (5)
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
Started Feb 2024
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
Started Jul 2020
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Started Sep 2019
103 enrolled
Chemotherapy-induced Nausea and Vomiting
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Started Nov 2018
690 enrolled
Malignant Neoplasm
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
Started Dec 2015
80 enrolled
Chemotherapy-Induced Nausea and VomitingLung Cancer
Loss of Exclusivity
LOE Date
Sep 18, 2035
116 months away
Patent Expiry
Sep 18, 2035